Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer

Clinical Colorectal Cancer

Volumn 3, Issue 2, 2003, Pages 108-112

  Cassinello, Javier ^a   Escudero, Pilar ^b   Salud, Antonieta ^c   Marcos, Fernando ^d   Pujol, Eduardo ^e   Pérez Carrión, Ramón ^f   Colmenarejo, Antonio ^g   González del Val, Ricardo ^h   Valero, José ⁱ   Oruezábal, Mauro J ^j   Guillem, Vicente ^k   García, Inés ^a   Arcediano, Alberto ^a   Marfà, Xavier ^l  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d HOSPITAL NUESTRA SEÑORA DEL PRADO   (Spain)

^e HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^f Clínica Conim   (Spain)

^g HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^h Hospital Alarcos   (Spain)

ⁱ Hospital General de Zamora   (Spain)

^j HOSPITAL GENERAL LA MANCHA CENTRO   (Spain)

^k Hospital 9 de Octubre   (Spain)

^l Sanofi Synthelabo   (Spain)

more..

Author keywords

Antitumoral activity; Bolus chemotherapy; Diarrhea; Neurosensory toxicity; Neutropenia

Indexed keywords

BILIRUBIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL OBSERVATION; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMPLANTATION; INTRAVENOUS CATHETER; LIVER DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; PAIN; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; SENSORY DYSFUNCTION; SURVIVAL TIME; VOMITING;

EID: 0041380999     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2003.n.017     Document Type: Article

References (24)

1. Faivre J, Bouvier AM, Bonithon-Kopp C. Epidemiology and screening of colorectal cancer. Best Pract Res Clin Gastroenterol 2002; 16:187-199.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80:827-841.
3. Extra JM, Marty M, Brienza S, et al. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998; 25:13-22.
4. Bleiberg H. Oxaliplatin (L-OHP): a new reality in colorectal cancer. Br J Cancer 1998; 77(suppl 4):1-3.
5. Cvitkovic E, Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 1999; 26:647-662.
6. Faivre S, Raymond E, Rixe O. Preclinical synergy of oxaliplatin in combination with other antitumor agents. Ann Oncol 1998; 9(suppl 4):131 (Abstract #627).
7. Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9:1053-1071.
8. Wiseman LR, Adkins JC, Plosker GL, et al. Oxaliplatin: a review of its use in the management of metastatic colorectal cancer. Drugs Aging 1999; 14:459-475.
9. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
10. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-147.
11. Figer A, Louvet C, Homerin M. Analysis of the prognostic factors of overall survival in the randomized trial of bimonthly leucovorin and FU regimen with and without oxaliplatin in advanced colorectal cancer. Proc Am Soc Clin Oncol 1999; 18:239a (Abstract #918).
12. Marantz A, López J, Ivulich C, et al. First line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin in metastasic colorectal cancer patients. Proc Am Soc Clin Oncol 1999; 18:292a (Abstract #1120).
13. Roca E, Montiel M, Barugel M, et al. 5-FU and leucovorin (Mayo regimen) plus bi-monthly oxaliplatin in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1999; 18:298a (Abstract #1144).
14. Zori Comba A, Blajman C, Rischardet E, et al. Biomonthly oxaliplatin with or without fluorouracil and leucovorin: proven evidence of synergism in a phase II randomized trial. Proc Am Soc Clin Oncol 1999; 18:248a (Abstract #953).
15. Sun Y, Guan Z, Jin M, et al. A multicenter randomized phase II trial of oxaliplatin alone and in combination in patients with advanced colorectal cancer in China. Proc Am Soc Clin Oncol 1999; 18:255a (Abstract #979).
16. Van Custem E, Szanto J, Rotha A, et al. Evaluation of the addition of oxaliplatin to the same Mayo or German 5-FU regimen in advanced refractory colorectal cancer. Proc Am Soc Clin Oncol 1999; 18:234a (Abstract #900).
17. Vassilaki M, Tsiapara S, Desse N, et al. First line chemotherapy with oxaliplatin + 5-fluorouracil + leucovorin in patients with metastasic colorectal cancer. Preliminary results of a phase II study. Proc Am Soc Clin Oncol 1999; 18:303a (Abstract #1164).
18. Cassinello J, Alvarez A, Lopez-Martin J, et al. Weekly 5-fluorouracil modulated with high dose levofolinic acid as front line chemotherapy in advanced colorectal carcinoma (ACRC). Proc Am Soc Cin Oncol 1999; 18:280a (Abstract #1074).
19. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998; 16:2739-2744.
20. Grothey A, Deschler B, Krening H, et al. Phase III study of bolus 5-fluorouracil (folinic acid (Mayo) vs weekly high-dose 24 h %-FU infusional/FA + oxaliplatin in advanced colorectal cancer. Proc Am Soc Clin Oncol 2002; 21:129a (Abstract #512).
21. Goldberg R, Morton R, Sargent D, et al. N9741: oxaliplatin or CPT-11 + 5-fluorouracil/folinic acid leucovorin or oxaliplatin + CPT-11 in advanced colorectal cancer: initial toxicity and response data from a GI Intergroup Study. Proc Am Soc Clin Oncol 2002; 21:128a (Abstract #511).
22. Zori Comba A, Blajman C, Richardet E, et al. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer 2001; 37:1006-1013.
23. Hoscher H, Chachoua A, Seller J, et al. First line activity of oxaliplatin and weekly bolus 5-FU and low-dose leucovorin in advanced colorectal cancer. Proc Am Soc Clin Oncol 2001; 20:138a (Abstract #548).
24. Giornelli G, Roca E, Chacon M, et al. Bimonthly oxaliplatin and weekly bolus 5-FU and folinic acid in patients with metastasic colorecal cancer: a feasible and active regimen. Proc Am Soc Clin Oncol 2002; 2000:295a (Abstract #1153).